Cytosorbents Corporation (FRA:HQE1)

Market Cap	32.33M -40.0%
Revenue (ttm)	31.57M +4.1%
Net Income	-6.98M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	250
Open	0.4955
Previous Close	0.5260
Day's Range	0.4955 - 0.4955
52-Week Range	0.4955 - 1.2200
Beta	n/a
RSI	39.68
Earnings Date	Mar 25, 2026

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, su...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1997
• Employees: 149
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HQE1

Financial Performance

In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.13% compared to the previous year's $35.59 million. Losses were -$8.20 million, -60.43% less than in 2024.

Financial numbers in USD